Donatello Crocetta, Chief Medical Officer at UCB, said: “These results for bimekizumab show meaningful improvements in inflammatory lesions and skin pain to three years, and offer a valuable ...

Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast ...

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of DT-7012, a ...

Evotec SE has announced a $25m milestone payment from Bristol Myers Squibb, recognising scientific progress made within their ...

Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of ...

ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal ...

Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...

New data from the PROCLIPI study has shown a meaningful overall survival benefit for patients with advanced cutaneous T-cell ...

Astellas Pharma has unveiled encouraging preliminary findings from its ongoing phase 4 OPTION-VMS observational study, ...

Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical ...